BIO vs. GMAB: Bio-Rad Laboratories vs. Genmab Stock Comparison
How do Bio-Rad Laboratories (BIO) and Genmab (GMAB) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Bio-Rad Laboratories (BIO) and Genmab (GMAB) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO is classified in Life Sciences Tools & Services while GMAB is classified in Biotechnology.
Bio-Rad Laboratories (BIO) trades as ordinary local shares, while Genmab (GMAB) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | BIO | GMAB |
|---|---|---|
| Name | Bio-Rad Laboratories Inc. | Genmab A/S American Depositary Shares |
| Country/Region | United States | Denmark |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Biotechnology |
| GICS Sub-Industry | Life Sciences Tools & Services | Biotechnology |
| Market Capitalization | 10.26 billion USD | 32.98 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | February 27, 1980 | June 1, 2009 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BIO | GMAB |
|---|---|---|
| Total Return (1Y) | 28.31% | 91.17% |
| Total Return (3Y, Annualized) | 8.52% | 20.70% |
| Total Return (5Y, Annualized) | -11.74% | 3.98% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BIO | GMAB |
|---|---|---|
| Volatility (1Y, Annualized) | 36.50% | 45.68% |
| Beta (5Y) | 1.03 | 0.72 |
| Max Drawdown (5Y) | -72.24% | -61.79% |
| Avg. Volume (3M) | 250.78K | 4.09M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BIO | GMAB |
|---|---|---|
| Sharpe Ratio (1Y) | 0.66 | 1.90 |
| Sortino Ratio (1Y) | 0.98 | 3.82 |
Profitability
ROE (TTM)
Both Bio-Rad Laboratories (BIO) at 14.27% and Genmab (GMAB) at 12.07% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.27%
- Max
- 109.18%
- BIO
- 14.27%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
12.07%
- Max
- 109.18%
- GMAB
- 12.07%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Bio-Rad Laboratories (BIO) at 39.45% keeps the most of each sales dollar — above its industry’s net margin range — and Genmab (GMAB) at 16.97% also retains a top-quartile share.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.45%
- BIO
- 39.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.97%
- Max
- 18.05%
- GMAB
- 16.97%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Genmab (GMAB) at 37.15% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.82%
- Max
- 83.12%
- Q3
- 14.77%
- BIO
- 11.82%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
37.15%
- Max
- 83.12%
- GMAB
- 37.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BIO | GMAB |
|---|---|---|
| ROE (TTM) | 14.27% | 12.07% |
| ROA (TTM) | 1.50% | 8.24% |
| Net Margin (TTM) | 39.45% | 16.97% |
| Operating Margin (TTM) | 11.82% | 37.15% |
| Gross Margin (TTM) | 52.19% | 92.67% |
Growth
Revenue Growth
Both Bio-Rad Laboratories (BIO) at 0.65% and Genmab (GMAB) at 19.19% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Genmab (GMAB) reports EPS growth of -9.23%, ranked against its industry; Bio-Rad Laboratories (BIO) has no EPS growth figure this period.
Growth Metrics
| Metric | BIO | GMAB |
|---|---|---|
| Revenue Growth (YoY) | 0.65% | 19.19% |
| Revenue Growth (3Y CAGR) | -2.68% | 21.23% |
| EPS Growth (YoY) | -- | -9.23% |
| EPS Growth (3Y CAGR) | -- | 8.48% |
Financial Strength
Current Ratio (MRQ)
Bio-Rad Laboratories (BIO) at 3.18 keeps current ratio within its industry’s typical mid-range, while Genmab (GMAB) at 2.45 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GMAB.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.18
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- BIO
- 3.18
- Q1
- 2.47
- Min
- 0.10
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.45
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- GMAB
- 2.45
- Min
- 0.10
Debt / Equity (MRQ)
Bio-Rad Laboratories (BIO) at 0.18 carries an industry-typical debt-to-equity mix, while Genmab (GMAB) at 0.82 uses more debt funding than most peers.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.18
- Max
- 1.42
- Q3
- 0.65
- BIO
- 0.18
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.82
- Max
- 1.42
- GMAB
- 0.82
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BIO | GMAB |
|---|---|---|
| Current Ratio (MRQ) | 3.18 | 2.45 |
| Debt / Equity (MRQ) | 0.18 | 0.82 |
| Net Debt / EBITDA | -0.73 | 2.45 |
Dividends
Dividend Yield (TTM)
Neither Bio-Rad Laboratories (BIO) nor Genmab (GMAB) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- GMAB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Bio-Rad Laboratories (BIO) nor Genmab (GMAB) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- GMAB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BIO | GMAB |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while Genmab (GMAB) at 45.84 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.14
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- BIO
- 10.14
- Min
- 0.07
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.84
- Max
- 85.34
- GMAB
- 45.84
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Bio-Rad Laboratories (BIO) at 3.96 and Genmab (GMAB) at 7.68 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.96
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIO
- 3.96
- Q1
- 3.01
- Min
- 0.01
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.68
- Max
- 58.18
- Q3
- 25.77
- GMAB
- 7.68
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Bio-Rad Laboratories (BIO) at 1.35 sits in the lower P/B ratio quartile against book while Genmab (GMAB) at 5.36 is valued near its industry’s middle — BIO is cheaper on assets, though weigh it against ROE and asset quality.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BIO
- 1.35
- Min
- -5.59
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.36
- Max
- 13.53
- Q3
- 6.54
- GMAB
- 5.36
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BIO | GMAB |
|---|---|---|
| P/E Ratio (TTM) | 10.14 | 45.84 |
| P/S Ratio (TTM) | 3.96 | 7.68 |
| P/B Ratio (MRQ) | 1.35 | 5.36 |
| Free Cash Flow Yield (TTM) | 2.65% | 2.59% |